EBS - Emergent-produced J&J vaccine distribution paused in several countries - NYT

Distribution of millions of doses of Johnson & Johnson's (JNJ) COVID-19 vaccine are on hold in Canada, Europe and South Africa because they were made at an Emergent BioSolutions (EBS) plant with manufacturing issues, according to The New York Times.Authorities in those countries want to make sure those shots are safe given that a manufacturing foul-up in March at an Emergent plant led to 15M J&J doses being tossed.The newspaper reports that about 6M to 9M doses are on hold because they came from lots produced in the same manufacturing area and over the same period in late February when the accidental mix-up occurred.None of the J&J shots manufactured at the Baltimore facility have been administered in the U.S.Johnson & Johnson (JNJ) shares are up 0.2% to $167.43 and Emergent shares are down 0.1% to $60.94.

For further details see:

Emergent-produced J&J vaccine distribution paused in several countries - NYT